Keyphrases
Alzheimer's Disease
69%
Dominantly Inherited Alzheimer's Disease
65%
Clinical Trials
52%
Autosomal Dominant Alzheimer's Disease
48%
Dominantly Inherited Alzheimer Network
36%
Symptom Onset
32%
Gantenerumab
28%
Rate of Change
27%
Mutation Carriers
25%
Solanezumab
21%
Disease Progression
21%
Sporadic Alzheimer's Disease
21%
Non-carriers
18%
Alzheimer's Disease Clinical Trials
17%
Longitudinal Change
17%
Clinical Outcomes
17%
Cerebrospinal Fluid
17%
Standardized Uptake Value
15%
Multiple Sclerosis
15%
Pittsburgh Compound B
13%
Treatment Effect
13%
Mixed Model Repeated Measures
13%
Prevention Trials
12%
DIAN-TU
12%
Dementia
12%
Linear Mixed Model
12%
Placebo
11%
Mini-Mental State Examination
10%
Total tau
10%
Biomarker Changes
10%
Cognitive Decline
10%
Amyloid Burden
10%
Alzheimer's Disease Prevention
10%
Mild Cognitive Impairment
10%
Longitudinal Data
10%
Positron Emission Tomography
10%
Neurodegeneration
10%
Early Alzheimer's Disease
10%
Disease Progression Modeling
10%
Practice Effects
10%
Sample Size Re-estimation
10%
Cognitive Impairment
9%
Decline Rate
9%
Progression Rate
8%
Disease Stage
8%
Alzheimer's Disease Biomarkers
8%
Disease Course
8%
Cognitive Outcome
8%
Biomarker Profile
8%
Clinical Dementia Rating
8%
Medicine and Dentistry
Alzheimer's Disease
100%
Amyloid Protein
43%
Biological Marker
36%
Gantenerumab
27%
Clinical Trial
26%
Autosomal Dominant Inheritance
25%
Positron Emission Tomography
21%
Solanezumab
21%
Cerebrospinal Fluid
20%
Tau
18%
Diseases
12%
Placebo
12%
Observational Study
10%
Pittsburgh Compound B
10%
Multiple Sclerosis
10%
Radioactive Tracer
10%
Presenilin 1
10%
Standardized Uptake Value
9%
Disease Exacerbation
8%
Polyethylene Terephthalate
7%
Neurodegeneration
7%
Neuroinflammation
7%
Amyloid Plaque
6%
Clinical Dementia Rating
6%
Mini-Mental State Examination
6%
Carbon 11
6%
Prophylaxis
5%
Amyloidosis
5%
Alzheimer's Disease Clinical Trial
5%
Treatment Effect
5%
Comorbidity
5%
Tumor Marker
5%
Cross Sectional Study
5%
Early-Onset Alzheimer's Disease
5%
Cerebral Atrophy
5%
Subgroup Analysis
5%
Patient with Alzheimer's Disease
5%
Triple Negative Breast Cancer
5%
Latent Class Analysis
5%
Down Syndrome
5%
Randomized Clinical Trial
5%
Health Behavior
5%
Electroencephalography Monitoring
5%
Signaling Mechanism
5%
Monoclonal Antibody
5%
Florbetapir (18F)
5%
Intensive Care Unit
5%
Alzheimer Disease Assessment Scale
5%
Glasgow Coma Scale
5%
Small Vessel Disease
5%
